Loading clinical trials...

Water-only Fasting in the Treatment of Hypertension Patients | Clinical Trials | Clareo Health

COMPLETEDNA

Water-only Fasting in the Treatment of Hypertension Patients

A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients

NCT04515095•TrueNorth Health Foundation

Summary

This purpose of this study is to examine the safety and feasibility of water-only fasting to treat hypertensive patients.

Detailed Description

This is a prospective, open label, single arm, intervention study to examine the safety and feasibility of water-only fasting to treat hypertensive patients. Additional aims include describing mean changes in resting blood pressure as well as markers of cardiovascular health and inflammation between baseline and end of fast, end of refeed, 6-weeks post departure, and 12-months after 6-weeks follow-up.

Eligibility

Age

30 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Any gender
•2. 30-75 years old
•3. Diagnosis of Stage 1 or 2 hypertension
•4. Fasting plasma glucose \<126mg/dL and/or hemoglobin A1c \<7 percent
•5. Elect and qualify for a water-only fast of at least 7 consecutive days
•6. Provide informed consent
•7. Internet and computer access
•8. Able to go to LabCorp for 6-week follow-up visit
•9. Willing/able to collect 24-hour urine sample prior to water-only fasting

Exclusion Criteria

•1. Systolic Blood Pressure/Diastolic Blood Pressure \>180/120 mmHg
•2. Active malignancy
•3. Active kidney disease (creatinine over 2.0)
•4. Active inflammatory disorder including classic autoimmune connective tissue (Lupus, Sjogrens, ANCA), multiple sclerosis, and inflammatory bowel disorders (Ulcerative colitis, Crohn's)
•5. Stroke, heart attack, deep vein thrombosis, atrial fibrillation, anticoagulant therapy, or pulmonary embolism within the last 12 months
•6. Inability to discontinue medications or supplements
•7. Abdominal metal implants
•8. Inability to consume only plant food for at least 48 hours before fast begins.
•9. Unable to lay still on the back for at least 10 min.

Locations (1)

TrueNorth Health Center

Santa Rosa, California, United States

Key Dates

Start Date

August 16, 2020

Primary Completion Date

September 29, 2021

Completion Date

December 1, 2022

Last Updated

November 22, 2023

Enrollment

ACTUAL participants

Conditions

Hypertension

Interventions

Water-only Fasting

OTHER

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGPHASE2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 22, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Water-only Fasting in the Treatment of Hypertension Patients

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets